Health Utility Values of Canadian Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Author(s)

MEIR LEVI, M.Sc.;
MUHC - McGill University Health Center, Cedars Cancer Centre, Montreal, QC, Canada

Presentation Documents

OBJECTIVES: The EuroQol 5-Dimension 5-Level (EQ-5D-5L) is a validated tool that assesses health utility (HU) as a measure of health-related quality of life (HRQoL). Contemporary data on HU of Canadian patients with metastatic breast cancer (mBC) by HER2 status is scarce, and thus this study sought to characterize HU values for HER2-negative (HER2-) mBC.
METHODS: A cross-sectional study was conducted at McGill University Health Centre in Quebec. Eligible patients were aged ≥18 years, had at least stable disease, and were on active treatment with a Health Canada-approved regimen for HER2- mBC (any line/time point on treatment). The EQ-5D-5L was administered at each visit, and each record was treated as a unique data point. The HU values were derived using the Canadian algorithm developed by Xie et al., 2016. The EQ-5D-5L measures HRQoL across five domains and is scored on 5 levels. The questionnaire included a visual analogue scale (VAS) where respondents ranked their overall health on scale of 0-100. Secondary outcomes included mean HU in specific subgroups: HER2-low, defined as immunohistochemistry (IHC) 1+ or IHC 2+/fluorescence in situ hybridization (FISH)-negative, and hormone receptor-positive and -negative (HR+ and HR-).
RESULTS: Between December 2022 and July 2023, 115 HER2- data points were included for analysis, representing 47 patients. For these patients, mean age was 60.1 years (SD: 11.7). The majority of patients were on second line of therapy (41.9%). The mean HU overall was 0.78 (SD: 0.16, n=115) and mean VAS was 74.32 (SD: 17.32). For HER2-low (n=98), mean HU was 0.77 (SD: 0.17). In the HR+/HER2- group, mean HU was 0.79 (SD: 0.15, n=84) and in the HR-/HER2- group, mean HU was 0.78 (SD: 0.20, n=31).
CONCLUSIONS: This study provides the first Canadian data on HU values for HER2- mBC patients, including emerging breast cancer classifications such as HER2-low.

Conference/Value in Health Info

2025-05, ISPOR 2025, Montréal, Quebec, CA

Value in Health, Volume 28, Issue S1

Code

PCR84

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes

Disease

SDC: Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×